Short answer
Scholar Rock Holding Corp (SRRK) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). Exhibits 99.1 and 99.2 furnished under Regulation FD, not treated as filed under Exchange Act Section 18.
Scholar Rock Holding Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibits 99.1 and 99.2 furnished under Regulation FD, not treated as filed under Exchange Act Section 18
- Limited liability protections for the company regarding exhibit contents
- Exhibits excluded from automatic incorporation into other SEC filings unless specifically referenced
Item 8.01 · Other Events
- FDA approval of ISEMBYLD™ (apitegromab-mstn) for spinal muscular atrophy
- Label covers adults and children aged 2 years and older receiving survival SMN2-targeted treatment
- Commercial launch opportunity in SMA, expanding Scholar Rock’s potential revenue base
- Approval removes a key regulatory hurdle and shifts focus to market access and commercialization execution
Item EX-99.1 · Exhibit EX-99.2
- FDA approval transforms Scholar Rock into a commercial-stage company with ISEMBYLD for SMA patients ≥2 years receiving SMN2-targeted therapy
- Phase 3 SAPPHIRE showed 2.2-point HFMSE improvement versus placebo at 10 mg/kg, with nominal p=0.0121
- Clinically meaningful response in 34.2% of treated patients versus 13.5% on placebo, odds ratio 3.8
- U.S. launch underway, with product expected to ship in coming days and patient-support infrastructure active
- Fracture risk is a key commercial and safety consideration, occurring in 9% of treated patients versus 2% on placebo
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Scholar Rock Holding Corp 8-K filings
Get the next SRRK 8-K as it lands
Follow SRRK for push alerts, or ask the research agent what this filing means.